STAT6 and prostate carcinoma: According to Jia et al. (Jia et al., 2022), prostate cancer cell-derived small lipid molecule lipoxin A4 (LXA4) could inhibit METTL3, and the decreased METTL3 promotes signal transducers and activators of transcription 6 (STAT6) phosphorylation, which in turn induces M2 macrophage polarization and enhances tumour progression.